Global Deletion of 11β-HSD1 Prevents Muscle Wasting Associated with Glucocorticoid Therapy in Polyarthritis

J.M. Webster*, M.S. Sagmeister, C.G. Fenton, A.P. Seabright, Y.C. Lai, S.W. Jones, A. Filer, M.S. Cooper, G.G. Lavery, K. Raza, R. Langen, R.S. Hardy

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

2 Citations (Web of Science)

Abstract

Glucocorticoids provide indispensable anti-inflammatory therapies. However, metabolic adverse effects including muscle wasting restrict their use. The enzyme 11beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1) modulates peripheral glucocorticoid responses through pre-receptor metabolism. This study investigates how 11 beta-HSD1 influences skeletal muscle responses to glucocorticoid therapy for chronic inflammation. We assessed human skeletal muscle biopsies from patients with rheumatoid arthritis and osteoarthritis for 11 beta-HSD1 activity ex vivo. Using the TNF-alpha-transgenic mouse model (TNF-tg) of chronic inflammation, we examined the effects of corticosterone treatment and 11 beta-HSD1 global knock-out (11 beta KO) on skeletal muscle, measuring anti-inflammatory gene expression, muscle weights, fiber size distribution, and catabolic pathways. Muscle 11 beta-HSD1 activity was elevated in patients with rheumatoid arthritis and correlated with inflammation markers. In murine skeletal muscle, glucocorticoid administration suppressed IL6 expression in TNF-tg mice but not in TNF-tg(11 beta KO) mice. TNF-tg mice exhibited reductions in muscle weight and fiber size with glucocorticoid therapy. In contrast, TNF-tg(11 beta KO) mice were protected against glucocorticoid-induced muscle atrophy. Glucocorticoid-mediated activation of catabolic mediators (FoxO1, Trim63) was also diminished in TNF-tg(11 beta KO) compared to TNF-tg mice. In summary, 11 beta-HSD1 knock-out prevents muscle atrophy associated with glucocorticoid therapy in a model of chronic inflammation. Targeting 11 beta-HSD1 may offer a strategy to refine the safety of glucocorticoids.
Original languageEnglish
Article number7828
Number of pages14
JournalInternational Journal of Molecular Sciences
Volume22
Issue number15
DOIs
Publication statusPublished - 1 Aug 2021

Keywords

  • sarcopenia
  • myopathy
  • steroids
  • adverse effects
  • 11beta hydroxysteroid dehydrogenase type 1
  • rheumatoid arthritis
  • inflammation
  • TUMOR-NECROSIS-FACTOR
  • DEHYDROGENASE TYPE-1
  • EXPRESSION
  • INHIBITION
  • METABOLISM
  • PROFILES

Cite this